恒指跌幅曾扩至逾600点险守牛熊线 濠赌及中资保险股捱沽
中国武汉市新型冠状病毒感染肺炎确诊个案最新续增至571宗，死亡病例增至17宗，武汉市今早10时起「封城」。美股期货全面反覆受压，昨晚逆市倒跌的道指期货报29,083，反覆续跌57点或0.2%。亚太区主要股市普遍受压，尤其是沪指及深成午後低见2,960及10,572，现造2,970及10,639，急吐2.9%及3.9%。
本港首次出现两宗高度怀疑感染武汉肺炎个案。恒指继昨天弹近1.3%受制28,400後，今天低开231点，跌幅持续曾扩至626点或2.2%，低见27,714，险守牛熊线(27,704)，现造27,764，急吐576点或2%，成交额已达786亿元。
蓝筹股无一幸免，跌幅普遍逾1%-3%。拟发7.5亿欧元零息可换股债券的中生制药(01177.HK)沽压最大，股价失守10天线，最低见11.4元，现造11.42元，急吐5.8%。石药(01093.HK)由今早高位19.68元，掉头低见18.68元，现造18.78元，倒跌3.6%。
联通(00762.HK)业绩快报料去年纯利按年增近11%至113亿人民币，该股失守50天及10天线(7.09-7.13元)，报6.83元，挫4.3%。此外，吉利(00175.HK)失守牛熊线(13.92元)，最低见13.44元，现造13.48元，挫4.4%。三大科技股跌逾2.5%-4%，瑞声(02018.HK)沽压最大，报61.8元。
澳门确诊第二宗武汉肺炎，金沙(01928.HK)及银娱(00027.HK)低见40元及54.5元，现造40.45元及54.8元，跌3.6%及4.9%，後者失守50天线(55.88元)。非蓝筹永利(01128.HK)、澳博(00880.HK)、美高梅(02282.HK)及新濠(00200.HK)也挫4.2%-6%，分别报17.94元/9.12元/12.28元/18.46元。
忧武汉肺死亡病例续增拖累理赔个案上升，国寿(02628.HK)跌破50天线(21.09元)，最低见20.35元，现造20.5元，挫4%；中国平安(02318.HK)失守10天线(95.8元)，最低见93元，现造93.35元，跌2.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
